NYSE:CRGY 16 December 2025

Crescent Energy stock jumps in premarket as oil spikes; CRGY nears 52-week high

Crescent Energy shares rose 5.8% to $12.33 in premarket trading Monday, nearing a 52-week high after oil prices surged on Middle East conflict fears. Brent crude jumped 8.3% to $78.92 a barrel; WTI climbed 7.8% to $72.24. Crescent reaffirmed a $0.12 dividend and raised its share buyback authorization to $400 million.

2 March 2026

Energy·NYSE:CRGY·Oil Prices

Crescent Energy Company Stock (CRGY) Slides on Dec. 16 After Vital Energy Deal Closes — Latest News, Analyst Forecasts, and What to Watch

Crescent Energy shares fell about 7% to $8.30 on December 16 after the company closed its all-stock acquisition of Vital Energy. Trading volume was elevated as investors reacted to the deal, despite Evercore ISI resuming coverage with an “Outperform” rating and a $13 price target. The stock underperformed both the broader market and the energy sector. Crescent plans to issue pro forma 2026 guidance with its next earnings report.

16 December 2025

Energy Sector·NYSE:CRGY·NYSE:VET·Stock Market

Telix Pharmaceuticals Shares Surge 12.9% After TLX101-Px FDA NDA Resubmission and U.S. Manufacturing Expansion
March 20, 2026, 1:35 PM EDT. Telix Pharmaceuticals (ASX:TLX) jumped 12.9% following its March 2026 resubmission of the New Drug Application (NDA) for TLX101-Px (Pixclara) to the U.S. FDA. The investigational PET imaging agent targets brain cancer diagnosis, specifically glioma, with no current FDA-approved equivalents in the U.S. The resubmission includes new data after a prior Complete Response Letter and benefits from Orphan Drug and Fast Track designations. Concurrently, Telix's U.S. manufacturing build-out, including cyclotron orders for isotope production, aims to scale supply for future launches. While analysts project revenue of A$1.2 billion and earnings of A$111 million by 2029, the company faces risks from heavy R&D and manufacturing investments that may pressure margins if commercialization stalls. Investors are weighing potential near-term catalysts against execution and development uncertainties.